Microbot Medical Strengthens Global IP Portfolio with Canadian Notice of Allowance for a Patent Application for a Shunt Steno...
April 23 2019 - 07:00AM
As it continues to receive an overwhelming positive response from
global jurisdictions, Microbot Medical Inc. (NASDAQ: MBOT) expands
its IP portfolio as it receives a Notice of Allowance from the
Canadian Intellectual Property Office for Patent Application No.
2,850,279, which pertains to a device for the prevention of shunt
stenosis.
With this latest Notice of Allowance, the
Company now has 32 issued/allowed patents and 19 patent
applications pending worldwide.
“As we continue to make progress on our primary
clinical objectives, we have also excelled at expanding Microbot’s
innovative IP portfolio, globally,” commented Harel Gadot, CEO,
President and Chairman. “This latest allowance in Canada represents
another significant step toward achieving this goal and creating
value that cements our positions as an emerging global leader in
micro-robotics.”
The allowed patent application covers a system
for reducing venous stenosis associated with the use of
hemodialysis shunts. A clearing device is inserted, and exerted,
through a first bore, while dialyzed blood is being returned into
the blood vessel through a second bore. The clearing device may be
a passive device moved down the blood vessel by the blood flow or
an autonomous crawling device, such as the Company’s TipCAT™
device, which is based on a series of sequentially inflatable
chambers.
About Microbot Medical Inc.
Microbot™, which was founded in 2010 and
commenced operations in 2011, became a NASDAQ-listed company on
November 28, 2016. The Company specializes in transformational
micro-robotic medical technologies leveraging the natural and
artificial lumens within the human body. Microbot’s current
technological platforms, ViRob™, TipCAT™ and CardioSert™, are
comprised of three highly advanced technologies, from which the
Company is currently developing its first product candidate: The
Self-Cleaning Shunt, or SCS™, for the treatment of hydrocephalus
and Normal Pressure Hydrocephalus, or NPH. The Company also is
focused on the development of a Multi Generation Pipeline Portfolio
(MGPP) utilizing all technologies. Further information about
Microbot Medical is available at
http://www.microbotmedical.com.
The ViRob™ technology is a revolutionary
autonomous crawling micro-robot which can be controlled remotely or
within the body. Its miniature dimensions allow it to navigate
and crawl in different spaces within the human body, including
blood vessels, the digestive tract and the respiratory
system. Its unique structure gives it the ability to move in
tight spaces and curved passages as well as the ability to remain
within the human body for prolonged time. To learn more about
ViRob™, please visit
http://www.microbotmedical.com/technology/virob/.
TipCAT™ is a transformational self-propelled,
flexible, and semi-disposable locomotive device providing see &
treat capabilities within tubular lumens in the human body such as
the colon, blood vessels, and the urinary tract. Its locomotion
mechanism is perfectly suitable to navigate and crawl through
natural & artificial tubular lumens, applying the minimal
necessary pressure to achieve the adequate friction required for
gentle, fast, and safe advancement within the human body. To
learn more about TipCAT™, visit
http://www.microbotmedical.com/technology/tipcat/.
CardioSert™ technology contemplates a unique
combination of a guidewire and microcatheter, technologies that are
broadly used for endoluminal surgery. The CardioSert™ technology
features unique steering and stiffness control capabilities, and it
was originally developed to support interventional cardiologists in
crossing the most complex lesions called chronic total occlusion
(CTO) during percutaneous coronary intervention (PCI) procedures
and has the potential to be used in other spaces and applications,
such as peripheral intervention, neurosurgery and urology.
CardioSert™ was part of a technological incubator supported by the
Israel Innovation Authorities (formerly known as the Office of the
Chief Scientist, or OCS), and its device has successfully completed
pre-clinical testing.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects” and “estimates”) should also be considered
to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of
potential products, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights, and the outcomes with respect to
any litigation the Company is involved in from time to time
(including the success of any appeals). Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the businesses of Microbot Medical Inc.
particularly those mentioned in the cautionary statements found in
Microbot Medical Inc.’s filings with the Securities and Exchange
Commission. Microbot Medical disclaims any intent or obligation to
update these forward-looking statements.
Investor Contact: Michael Polyviou EVC Group
mpolyviou@evcgroup.com 732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2023 to Mar 2024